NUWE

Nuwellis, Inc. [NUWE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NUWE Stock Summary

Top 10 Correlated ETFs

NUWE


Top 10 Correlated Stocks

NUWE


In the News

09:00 28 Mar 2024 NUWE

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

08:42 28 Mar 2024 NUWE

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system

11:18 28 Mar 2024 NUWE

Here's Why Nuwellis, Inc. (NUWE) Is a Great 'Buy the Bottom' Stock Now

Nuwellis, Inc. (NUWE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

02:06 28 Mar 2024 NUWE

Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript

Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - Chief Medical Officer Rob Scott - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Nuwellis third-quarter 2023 earnings conference call. [Operator Instructions].

04:15 28 Mar 2024 NUWE

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

04:15 28 Mar 2024 NUWE

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET.

09:19 28 Mar 2024 NUWE

Why Is Nuwellis (NUWE) Stock Down Today?

Nuwellis (NASDAQ: NUWE ) stock is taking a beating on Monday despite a lack of news concerning the medical device company. In fact, there's really not much in the way of anything to report about Nuwellis stock today.

04:15 28 Mar 2024 NUWE

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

04:15 28 Mar 2024 NUWE

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

08:00 28 Mar 2024 NUWE

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview.

NUWE Financial details

Company Rating
Neutral
Market Cap
2.97M
Income
-20.21M
Revenue
8.86M
Book val./share
0.84
Cash/share
1.07
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-0.07
Forward P/E
-0.27
PEG
0.01
P/S
0.22
P/B
0.14
P/C
0.37
P/FCF
-0.1
Quick Ratio
2.12
Current Ratio
3.22
Debt / Equity
0.15
LT Debt / Equity
0.07
-
-
EPS (TTM)
-12.78
EPS next Y
-1.48
EPS next Q
-0.94
EPS this Y
-87.68%
EPS next Y
-88.42%
EPS next 5Y
-88.42%
EPS last 5Y
-75.49%
Revenue last 5Y
9.97%
Revenue Q/Q
5.76%
EPS Q/Q
-13.81%
-
-
-
-
SMA20
-31.75%
SMA50
-17.31%
SMA100
-51.69%
Inst Own
7855.09%
Inst Trans
1.18%
ROA
-145%
ROE
-148%
ROC
-2.2%
Gross Margin
57%
Oper. Margin
-215%
Profit Margin
-192%
Payout
-
Shs Outstand
6.8M
Shs Float
6.8M
-
-
-
-
Target Price
-
52W Range
0.39-5.73
52W High
-
52W Low
-
RSI
36.9
Rel Volume
0.17
Avg Volume
903.62K
Volume
153.01K
Perf Week
-9.95%
Perf Month
-13.77%
Perf Quarter
-60.23%
Perf Half Y
-72.84%
-
-
-
-
Beta
0.181
-
-
Volatility
0.02%, 0.09%
Prev Close
-3.95%
Price
0.3938
Change
-7.43%

NUWE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.54K451.24114.849.144.51
Net income per share
-11.63K-960.34-283.74-83.55-10.29
Operating cash flow per share
-10.51K-1K-259.13-87.14-9.13
Free cash flow per share
-10.82K-1.02K-262.3-87.84-9.26
Cash per share
820.92875.5574.9105.31.93
Book value per share
1.28K989.57376.0471.081.52
Tangible book value per share
1.28K989.57376.0471.081.52
Share holders equity per share
1.28K989.57376.0471.081.52
Interest debt per share
286.9120.5617.0658.852
Market cap
4.02M11.49M7.87M1.86M1.14M
Enterprise value
3.19M-2.6M-15.16M-14.89M-1.68M
P/E ratio
-0.22-0.73-0.4-0.13-0.06
Price to sales ratio
0.731.540.990.220.13
POCF ratio
-0.25-0.69-0.44-0.12-0.06
PFCF ratio
-0.24-0.68-0.43-0.12-0.06
P/B Ratio
2.020.70.30.150.38
PTB ratio
2.020.70.30.150.38
EV to sales
0.58-0.35-1.91-1.74-0.19
Enterprise value over EBITDA
-0.180.150.80.890.1
EV to operating cash flow
-0.190.160.850.980.09
EV to free cash flow
-0.190.150.840.980.09
Earnings yield
-4.51-1.38-2.49-7.79-17.71
Free cash flow yield
-4.19-1.47-2.3-8.19-15.94
Debt to equity
0.220.020.050.080.15
Debt to assets
0.080.020.040.040.04
Net debt to EBITDA
0.050.791.2110.16
Current ratio
1.25.178.54.862.59
Interest coverage
000-1.86-5.06
Income quality
0.91.050.911.040.89
Dividend Yield
00002.01
Payout ratio
0000-0.11
Sales general and administrative to revenue
00000
Research and developement to revenue
0.850.490.630.510.61
Intangibles to total assets
00000
Capex to operating cash flow
0.030.020.010.010.01
Capex to revenue
-0.09-0.04-0.03-0.01-0.03
Capex to depreciation
-2.05-0.79-0.45-0.33-0.69
Stock based compensation to revenue
0.270.180.170.10.08
Graham number
18.28K4.62K1.55K365.5518.77
ROIC
-6.28-1-0.69-1.2-4.44
Return on tangible assets
-3.23-0.79-0.64-0.59-2.07
Graham Net
-536.1782.31538.8748.17-0.26
Working capital
685K14.95M24.82M18.08M5.04M
Tangible asset value
1.99M16.32M25.95M12.36M2.99M
Net current asset value
424K14.84M23.66M10.45M1.43M
Invested capital
0.220.020.050.080.15
Average receivables
792.5K852K827.5K1.08M1.68M
Average payables
1.31M1.29M1.26M1.83M2.31M
Average inventory
1.73M2.38M2.9M2.75M2.33M
Days sales outstanding
52.9244.3934.5660.0780.34
Days payables outstanding
204.18118.32150.47216.32223.83
Days of inventory on hand
246.58318.94302.53256.41187.81
Receivables turnover
6.98.2210.566.084.54
Payables turnover
1.793.082.431.691.63
Inventory turnover
1.481.141.211.421.94
ROE
-9.1-0.97-0.75-1.18-6.76
Capex per share
-314.51-18.07-3.17-0.7-0.13

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
6.171.621.561.30.72
Net income per share
-5-5.76-3.65-1.81-1.56
Operating cash flow per share
-8.25-5.42-3.95-2.05-0.78
Free cash flow per share
-8.3-5.51-4-2.12-0.77
Cash per share
48.310.746.72.651.07
Book value per share
32.612.148.344.210.84
Tangible book value per share
32.612.148.344.210.84
Share holders equity per share
32.612.148.344.210.84
Interest debt per share
26.991.390.660.441.11
Market cap
4.06M5.47M3.57M2.66M2.06M
Enterprise value
-12.69M-5.11M-4.45M-1.45M-763.09K
P/E ratio
-0.54-0.21-0.18-0.2-0.09
Price to sales ratio
1.7431.721.10.81
POCF ratio
-1.3-0.9-0.68-0.7-0.75
PFCF ratio
-1.29-0.88-0.67-0.67-0.76
P/B Ratio
0.330.40.320.340.69
PTB ratio
0.330.40.320.340.69
EV to sales
-5.43-2.8-2.14-0.6-0.3
Enterprise value over EBITDA
2.841.020.90.470.22
EV to operating cash flow
4.060.840.850.380.28
EV to free cash flow
4.030.820.840.370.28
Earnings yield
-0.47-1.19-1.36-1.27-2.68
Free cash flow yield
-0.77-1.13-1.49-1.48-1.32
Debt to equity
0.080.070.080.10.15
Debt to assets
0.040.050.060.070.04
Net debt to EBITDA
3.752.111.621.330.81
Current ratio
4.864.043.593.222.59
Interest coverage
-0.49-9.200-1.03
Income quality
1.650.941.081.140.5
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.510.780.730.460.54
Intangibles to total assets
00000
Capex to operating cash flow
0.010.020.010.03-0.01
Capex to revenue
-0.01-0.05-0.03-0.050.01
Capex to depreciation
-0.27-1.14-0.78-1.440.33
Stock based compensation to revenue
0.070.10.090.060.06
Graham number
60.5839.6626.1613.095.44
ROIC
-0.32-0.38-0.39-0.33-0.91
Return on tangible assets
-0.08-0.35-0.31-0.29-0.56
Graham Net
22.18.555.021.92-0.15
Working capital
18.08M12.5M9.92M6.65M5.04M
Tangible asset value
12.36M13.66M11.07M7.84M2.99M
Net current asset value
10.45M11.8M9.27M6.05M1.43M
Invested capital
0.080.070.080.10.15
Average receivables
1.25M1.35M1.24M1.3M1.69M
Average payables
1.9M2.38M2.42M2.01M2.04M
Average inventory
2.79M2.7M2.74M2.53M2.17M
Days sales outstanding
54.164.1251.0153.1768.83
Days payables outstanding
200.45299.29224.13149.01184.18
Days of inventory on hand
237.59325.14265.05203.92154.54
Receivables turnover
1.661.41.761.691.31
Payables turnover
0.450.30.40.60.49
Inventory turnover
0.380.280.340.440.58
ROE
-0.15-0.47-0.44-0.43-1.84
Capex per share
-0.05-0.09-0.05-0.060.01

NUWE Frequently Asked Questions

What is Nuwellis, Inc. stock symbol ?

Nuwellis, Inc. is a US stock , located in Eden prairie of Mn and trading under the symbol NUWE

What is Nuwellis, Inc. stock quote today ?

Nuwellis, Inc. stock price is $0.3938 today.

Is Nuwellis, Inc. stock public?

Yes, Nuwellis, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap